Journal of toxicology. Clinical toxicology (J Toxicol Clin Toxicol)
Reflecting the professional concerns and astute scientific judgment of the American Academy of Clinical Toxicology (AACT) and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT), the Journal of Toxicology - Clinical Toxicology serves as an international voice on the unique specialty of medical toxicology - presenting timely, peer-reviewed scientific research and clinical articles on all facets of acute and chronic poisoning and its management. The rapid proliferation of new drugs, toxin, antitoxins, and environmental hazards and the renewed threat of chemical warfare are pressing issues in emergency medicine. Certification in the subspecialty of Clinical Toxicology is now offered by the American Boards of Emergency Medicine (ABEM), Preventative Medicine (ABPM), and Pediatrics (ABP), reflecting the need for expertise in Acute toxicologic care, including hemodialysis hemoperfusion hepatic support systems liquid ventilatory perfusion Environmental exposures Civil Defense Occupational toxicology Substance abuse Analytic toxicology In addition, the journal furnishes opportunities for new insights and explications as well as consolidates consensus views on contemporary issues, offering state-of-the-art, evidence-based position papers on topics related to gastrointestinal decontamination and elimination techniques and guidelines ipecac, lavage and charcoal gastric lavage single and multiple dose activated charcoal cathartics whole bowel irrigation alkaline diuresis hemoperfusion hemodialysis and much more! about the sponsors... The American Academy of Clinical Toxicology (AACT) and the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) are organizations of clinical toxicologists primarily affiliated with teaching hospitals, schools of pharmacy and public health, and regional centers for poison information and treatment. Their professional activities include emergency and critical care; family practice; internal medicine; pediatrics; occupational, environmental, preventive, and public health; epidemiology; forensic and clinical chemistry; substance abuse; pharmacy; and research pharmacology and toxicology. Discontinued in 2005 - now Clinical Toxicology.
Current impact factor: 0.00
Impact Factor Rankings
|2016 Impact Factor||Available summer 2017|
|2006 Impact Factor||1.091|
|2005 Impact Factor|
|2004 Impact Factor||1.739|
|2003 Impact Factor||1.633|
|2002 Impact Factor||1.17|
|2001 Impact Factor||1.369|
|2000 Impact Factor||1.308|
|1999 Impact Factor||1.732|
|1998 Impact Factor||1.177|
|1997 Impact Factor||0.934|
Impact factor over time
|Website||Journal of Toxicology - Clinical Toxicology website|
|Other titles||Journal of toxicology. Clinical toxicology, Clinical toxicology|
|Material type||Periodical, Internet resource|
|Document type||Journal / Magazine / Newspaper, Internet Resource|
Publications in this journal
Article: Black Widow Spider Bites[Show abstract] [Hide abstract]
ABSTRACT: Black widow spiders (Latrodectus species) are found worldwide. Envenomation of humans usually occurs as the result of chance intrusion into the spider's domain by the human. The venom is regarded as one of the most potent biologic toxins. The venom acts by destabilization of cell membranes and degranulation of nerve terminals resulting in the release of neurotransmitters. The clinical picture is characterized by painful muscle spasm and hypertension. The very young, the elderly or enfeebled, and those with cardiovascular disease are at greatest risk. While not always necessary, the most effective treatment is specific antiserum. Muscle relaxants, analgesics and intravenous calcium are useful adjuvant treatment.
Article: Marine Envenomations[Show abstract] [Hide abstract]
ABSTRACT: As man takes increasing advantage of the waters of the world for recreational, commercial and scientific purposes, the hazards of human contact with inhabitants must be appreciated. Many invertebrate and vertebrate animal species have developed natural defense mechanisms, some of which involve envenomation, with a few species posing the threat of serious injury or death. This paper discusses the more common and more serious marine envenomations encountered worldwide, including toxicology of the associated venoms and a discussion of current treatment recommendations.
- [Show abstract] [Hide abstract]
ABSTRACT: Objective: To define the pharmacokinetics of continuous infusion pralidoxime in organophosphate-poisoned children. Study Design: Open-label study in 11 children and adolescents poisoned with organophosphates or carbamates. Serial blood samples were obtained during continuous pralidoxime infusion and after the drug was stopped. Results: Patients were treated for 12-43 hours. Steady-state concentrations were (mean ± SD) 22.2 ± 12.3 mg/L. Volume of distribution ranged from 1.7 to 13.8 L/kg and was significantly higher in the more severely poisoned subjects. Elimination half-life was 3.6 ± 0.8 hours, and clearance was 0.88 ± 0.55 L/h/kg. After initiation of continuous infusion pralidoxime, only 1 patient required any additional atropine to control recurrent muscarinic symptoms. All patients exhibited complete clinical recovery. Conclusions: The pharmacokinetics of pralidoxime in poisoned children following continuous intravenous infusion are widely variable and differ from those previously reported in both healthy and poisoned adults. A loading dose of 25-50 mg/kg is recommended followed by a continuous infusion of 10-20 mg/kg/h. A loading dose of 50 mg/kg may be appropriate in more severely poisoned patients.
- [Show abstract] [Hide abstract]
ABSTRACT: The Australian Small-scaled Snake, Oxyuranus microlepidotus , recently rediscovered, is the world's most venomous snake, with a murine LD50 of 0.01 mg/kg. Recently developed immunological techniques, combined with a whole animal model, have enabled us to measure accurately the mass of venom actually injected by a striking snake. The venom of this species contains at least six identified protein fractions, and one or more of these possesses potent neurotoxic action. An initial assessment of the molecular weights of each of these is reported. This study describes field biting experiments applicable to potential human snake-bite, and presents data concerning the injected venom:LD50 ratio which is an index of potential human lethality. This snake delivers an average mass of 17.3 mg in a strike, and the injected mass:LD50 ratio is 1730, the highest recorded for any snake. Comparative results for five other Elapidae whose venom contains potent neurotoxins are also presented. An average mass of 0.6 mg of venom is split on the skin surface during a strike, and 40% of this can be recovered within three hours after a simulated bite. As with other Elapidae studied to date, an adequate mass of venom remains on the skin for an accurate species diagnosis to be made in the case of human snake-bite.
- [Show abstract] [Hide abstract]
ABSTRACT: The utility of the toxicology laboratory in emergency medicine is directly related to both establishing communication between the toxicology laboratory and the clinical staff, and to providing reliable toxicology data while the diagnostic process is still in progress. When 604 patients, on whom a "complete toxicology screen" was requested, were evaluated using qualitative probes involving chemical spot tests, immunoassay, TLC and/or selected GC/HPLC methods, the resulting data were demonstrated to be of value. The ability of the clinician to accurately predict which, if any, of a large number of intoxicants were present in a given patient, was found to be minimal and as a result these combined tests were found to be essential in facilitating a proper diagnosis. Additionally, it was found that using only chemical spot tests, immunoassay and TLC in a combined qualitative approach detected 94-98% of all the substances eventually found within the population when it was further studied using more sophisticated instrumental methods. The integrated approach involving the initial establishment of a dialogue between the clinician and the toxicologist, use of simple qualitative analytical probes, confirmation of positive findings and prompt reporting of toxicology data is a viable way in which meaningful toxicology support can be provided while the diagnostic process is still underway.
- [Show abstract] [Hide abstract]
ABSTRACT: In rats and humans chronically exposed to large amounts of PCB (polychlorinated biphenyls) and PCDF (polychlorinated dibenzofurans), the urinary excretion of uroporphyrin and coproporphyrin are altered. However, porphyrin excretion in humans after acute transient low level exposure has not been evaluated. Following such an exposure in which bystanders and firefighters were in contact with smoke from a PCB transformer fire, we surveyed 90 self-referred individuals by questionnaire and by determining single 24 hour urinary excretion of uroporphyrin and coproporphyrin 2-4 weeks after the fire. Questionnaire variables that assessed exposure were not associated with the magnitude of either uroporphyrin or coproporphyrin excretion. Uroporphyrin excretion was slightly elevated in nine subjects (range 66-106 micrograms/24 hours, normal less than 60), which is much less than in clinical cases of porphyria cutanea tarda. Uroporphyrin excretion was inversely correlated with coproporphyrin excretion (r = -0.3844, p = 0.0002). For 5 subjects (3 with elevated initial uroporphyrin excretion) retested at 3-4 weeks after the fire, all 5 showed increases in uroporphyrin and decreases in coproporphyrin excretion when compared to initial determinations. These two reciprocal relationships would be the expected result from inhibition of uroporphyrinogen decarboxylase, a known experimental effect of PCB and PCDF in mice. Overall, urinary porphyrin excretions were not altered or sensitive measures of exposure.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.